Table 1.
Results of the diagnostic meta-analyses (hierarchical summary receiver operating characteristic curves)a
| Comparison with TN at-risk patients (no. of studies) | Illustration | Sensitivity | Specificity | DOR | Likelihood ratio |
|
|---|---|---|---|---|---|---|
| Positive | Negative | |||||
| TP I individuals (with candidemia) | ||||||
| Allb (49) | Fig. 1A; Fig. S3 in the supplemental material | 0.95 (0.88–0.98) | 0.92 (0.88–0.95) | 229.1 (85–617.3) | 12.3 (7.9–19.3) | 0.05 (0.02–0.14) |
| Yr, ≥2000b,c (27) | Fig. S4A in the supplemental material | 0.93 (0.91–0.97) | 0.94 (0.89–0.97) | 195.7 (70.9–540.4) | 15.4 (9–26.4) | 0.08 (0.03–0.21) |
| Subgroup analysis: whole blood; rRNA or p450 gene target; detection limit, ≤10 CFU/ml; SeptiFast excluded (23) | Fig. S5 in the supplemental material | 0.98 (0.85–1) | 0.90 (0.82–0.85) | 394.9 (56.4–2,765.4) | 10.2 (5.5–18.9) | 0.03 (0.004–0.18) |
| TP II individuals (with proven/probable IC) | ||||||
| Allb (17) | Fig. 1B | 0.93 (0.82–0.98) | 0.95 (0.87–0.98) | 251.9 (57.4–1,106) | 18.2 (7–47.2) | 0.07 (0.03–0.2) |
| Yr, ≥2000 (8) | Fig. S4B in the supplemental material | 0.87 (0.70–0.95) | 0.96 (0.92–0.98) | 178.9 (51.1–626.8) | 24.3 (11.3–52.4) | 0.14 (0.05–0.33) |
| TP III individuals (with proven/probable/possible IC) | ||||||
| All (20) | Fig. 1C | 0.73 (0.58–0.83) | 0.91 (0.82–0.96) | 26.9 (10.5–69.2) | 8.1 (4–16.5) | 0.3 (0.9–0.48) |
| Yr, ≥2000 (11) | Fig. S4C in the supplemental material | 0.71 (0.52–0.85) | 0.95 (0.92–0.97) | 47.3 (16.9–132.9) | 14.4 (8–25.2) | 0.3 (0.17–0.55) |
a
Values in parentheses are 95% confidence intervals.
b
Model fit using Stata's gllamm (generalized linear latent and mixed models) option.
c
Study end year. If the year when the study ended was not reported in the article, we used the publication year minus 2.